Product Name:4-((4-Methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline

IUPAC Name:4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)aniline

CAS:694499-26-8
Molecular Formula:C13H18F3N3
Purity:95%+
Catalog Number:CM169811
Molecular Weight:273.3

Packing Unit Available Stock Price($) Quantity
CM169811-10g in stock ǕƱƱ
CM169811-25g in stock ȦƋƋ
CM169811-100g in stock ƤƱɐ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:694499-26-8
Molecular Formula:C13H18F3N3
Melting Point:-
Smiles Code:NC1=CC=C(CN2CCN(C)CC2)C(C(F)(F)F)=C1
Density:
Catalog Number:CM169811
Molecular Weight:273.3
Boiling Point:
MDL No:MFCD09909924
Storage:Keep in dark place, store at 2-8°C.

Category Infos

Piperazines
Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.
Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Olverembatinib
Ascentage Pharma announced that updated results from three studies of olverembatinib, have been released in posters at the 2024 European Hematology Association Hybrid Congress, taking place in Madrid, Spain.
Olverembatinib (HQP1351) is an oral, third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) developed by Ascentage Pharma for the treatment of chronic myeloid leukaemia (CML), acute myeloid leukaemia, acute lymphoblastic leukaemia (ALL) and solid tumours, including gastrointestinal stromal tumours (GIST). Olverembatinib is an ATP binding-site inhibitor of wild type BCR-ABL1 kinase and a broad spectrum of BCR-ABL1 mutants, including mutant T315I, which confers resistance against all first- and second-generation TKIs. 

Related Products